NH600001, an etomidate analogue, provides gastrointestinal endoscopy sedation/anesthesia and reduces adrenocortical depression: two randomized controlled trials.

Summary

Across two multicenter, double-blind RCTs in GI endoscopy, NH600001 at 0.25 mg/kg achieved non-inferior procedure success versus etomidate 0.30 mg/kg, while the 0.20 and 0.30 mg/kg doses did not meet non-inferiority. The program assessed adrenocortical effects, consistent with the title’s finding of reduced adrenocortical depression with NH600001.

Key Findings

• In Phase II (n=160), NH600001 0.25 mg/kg was non-inferior to etomidate 0.30 mg/kg for endoscopic success (rate difference 5.0%; 95% CI −4.49 to 14.49).
• NH600001 0.20 mg/kg and 0.30 mg/kg did not meet the prespecified non-inferiority margin.
• Adrenocortical function was evaluated (cortisol AUC 0–4 h), aligning with the program’s goal to reduce etomidate-like adrenocortical depression.

Clinical Implications

NH600001 could become a preferred agent for GI endoscopy sedation/anesthesia where adrenal suppression is a concern, especially in patients at risk for hemodynamic instability or sepsis, pending broader regulatory approval and post-marketing safety data.

Limitations

• Abstract provides incomplete quantitative details on cortisol outcomes; longer-term endocrine safety not reported.
• Population limited to GI endoscopy; generalizability to other procedural settings requires study.

Future Directions

Confirm endocrine safety and dosing in broader procedural populations; head-to-head comparisons with propofol and other sedatives; real-world effectiveness and safety registries.